Breast cancer is a heterogeneous disease, with different subtypes having a distinct
biological, molecular, and clinical course. Assessments of standard clinical and pathological …

Cancer Biomarkers are the key to unlocking the promise of precision oncology, selecting
which patients will respond to a more personalised treatment while sparing non-responders …

Background Current staging systems for cutaneous squamous cell carcinoma (cSCC) have
limited positive predictive value for identifying patients who will experience metastasis …

More than 750 000 women in Italy are surviving a diagnosis of breast cancer. A large body
of literature tells us which characteristics impact the most on their prognosis. However, the …

Introduction EndoPredict (EP) is an RNA-based multigene test that predicts the likelihood of
distant recurrence in patients with estrogen receptor-positive (ER+), human epidermal …

Purpose Prior studies examining cost effectiveness of the 21-gene assay (Oncotype DX
[ODX]) for women with hormone receptor–positive, early-stage breast cancer have yielded …

Gene expression profiles with prognostic capacities have shown good performance in
multiple clinical trials. However, with multiple assays available and numerous types of …

Standard of care for high‐risk cutaneous squamous cell carcinoma (cSCC) is surgical
excision of the primary lesion with clear margins when possible, and additional resection of …

Atypical mitosis is considered a feature of malignancy, however, its significance in breast
cancer (BC) remains elusive. Here, we aimed to assess the clinical value of atypical mitoses …

BACKGROUND There is uncertainty about the chemotherapy sensitivity of some oestrogen
receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast …